NEW YORK, July 10 - Belgian genomics firm Galapagos Genomics said today it will use its PhenoSelect gene-expression tool to build recombinant adenoviruses for Bayer.
Through the deal, an expansion of an agreement signed in June 2001, Galapagos will help Bayer perform in vivo validation studies based on its undisclosed human genes. The drug giant said it plans to use the adenoviruses to express newly found genes in animal models to study corresponding proteins.
Click here for more information.